ENDPOINTS

Merck KGaA to buy rare cancer biotech SpringWorks for $3.9B

Merck KGaA said Monday it has inked a “definitive agreement” to acquire Pfizer spinout SpringWorks Therapeutics for an equity value of around $3.9 billion, rounding off several months of negotiations. The deal price of ...

Apr 28, 2025 - 13:20
 0
Merck KGaA to buy rare cancer biotech SpringWorks for $3.9B
Merck KGaA said Monday it has inked a “definitive agreement” to acquire Pfizer spinout SpringWorks Therapeutics for an equity value of around $3.9 billion, rounding off several months of negotiations. The deal price of ...
Read More

Tags:

Previous Article

This Bitcoin Encryption Comes from Renaissance Art and Math

Next Article

A forensic investigator of glacier change

Related Posts

Roche takes steps to protect itself from tariffs, while Sanofi hangs back

Roche takes steps to protect itself from tariffs, while...

Apr 24, 2025  0

The potential of all-AI labs

The potential of all-AI labs

Apr 24, 2025  0

Summit, Akeso report another Phase 3 win for PD-1xVEGF approach in lung cancer

Summit, Akeso report another Phase 3 win for PD-1xVEGF ...

Apr 23, 2025  0